New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)

被引：5

作者：

Moreno, Laura ^{[1
]}

Zabaleta, Aintzane ^{[2
]}

Alignani, Diego ^{[2
]}

Lasa, Marta ^{[3
]}

Maiso, Patricia ^{[4
]}

Jelinek, Tomas ^{[2
]}

Segura, Victor ^{[5
]}

Delgado, Jose Antonio ^{[1
]}

Rodriguez-Otero, Paula ^{[2
]}

Prosper, Felipe ^{[2
]}

Strein, Klaus ^{[6
]}

Vu, Minh Diem ^{[6
]}

Miguel, Jesus San ^{[7
]}

Paiva, Bruno ^{[8
]}

机构：

[1] Univ Navarra Clin, Dept Hematol & Immunol, Pamplona, Spain

[2] Univ Navarra Clin, Pamplona, Spain

[3] CIMA, Pamplona, Spain

[4] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[5] CIMA UNAV IDISNA, Dept Bioinformat, Pamplona, Spain

[6] EngMab AG, Wilen, Switzerland

[7] CIMA UNAV IDISNA, Pamplona, Spain

[8] Univ Navarra, Ctr Invest Med Aplicada, Univ Navarra Clin, Pamplona, Spain

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.2096.2096

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2096

引用

页数：5

共 46 条

[31] Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma
Wang, Baohui
Huang, Xiao
Sun, Jianming
Qin, Yurong
Shang, Hongyan
Li, Tingting
Wu, Guojin
Chen, Min
Wang, Hailin
Zhang, Peng
Jiang, Duqing
Liu, Tongjun
Ye, Mi
Cai, Shengli
Lai, Shoupeng
Kang, Xiaoqiang
Ling, Hong
BLOOD, 2023, 142
[32] A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Harrison, Simon J.
Minnema, Monique C.
Lee, Hans C.
Spencer, Andrew
Kapoor, Prashant
Madduri, Deepu
Larsen, Jeremy
Ailawadhi, Sikander
Kaufman, Jonathan L.
Raab, Marc S.
Hari, Parameswaran
Iida, Shinsuke
Vij, Ravi
Davies, Faith E.
Lesley, Robin
Upreti, Vijay V.
Yang, Zhao
Sharma, Anjali
Minella, Alex
Lentzsch, Suzanne
BLOOD, 2020, 136
[33] Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study.
Topp, Max S.
Duell, Johannes
Zugmaier, Gerhard
Attal, Michel
Moreau, Philippe
Langer, Christian
Kroenke, Jan
Facon, Thierry
Salnikov, Alexey
Lesley, Robin
Beutner, Karl
Kalabus, James
Rasmussen, Erik
Riemann, Kathrin
Minella, Alex C.
Munzert, Gerd Michael
Einsele, Hermann
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[34] Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL
Stefano, Sammicheli
Grandclement, Camille
Labanca, Valentina
De Angelis, Stefania
Estoppey, Carole
Chimen, Myriam
Pouleau, Blandine
Suere, Perrine
Nallet, Emilie
Srivastava, Ankita
Feldman, Eric J.
Proscurshim, Igor
Konto, Cyril
Zhukovsky, Eugene
Perro, Mario
BLOOD, 2022, 140 : 6237 - 6238
[35] A Phase 1 First-in-Human Study of Abbv-383, a BCMA x CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
Voorhees, Peter M.
D'Souza, Anita
Weisel, Katja
Hurd, David Duane
Teipel, Raphael
Chung, Alfred
Rodriguez, Cesar
Tuchman, Sascha A.
Korde, Neha
Safah, Hana
Bueno, Orlando F.
Pumford, Neil
Rosenberg, Tanya S.
Pothacamury, Rajvineeth Kumar
Ross, Jeremy A.
Polepally, Akshanth R.
Lee, Shane
Jin, Ziyi
Talati, Chetasi
Vij, Ravi
Kumar, Shaji K.
BLOOD, 2022, 140 : 4401 - 4404
[36] Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study
Topp, Max S.
Duell, Johannes
Zugmaier, Gerhard
Attal, Michel
Moreau, Philippe
Langer, Christian
Kroenke, Jan
Facon, Thierry
Einsele, Hermann
Munzert, Gerd
BLOOD, 2018, 132
[37] RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination
Eckmann, Jan
Fauti, Tanja
Zabaleta, Aintzane
Blanco, Laura
Kassem, Sahar
Carrie, Nadege
Lorenz, Stefan
Carpy, Alejandro
Christopeit, Tony
Fertig, Georg
Bernasconi, Luise
Biehl, Marlene
Diggelmann, Sarah
Knobloch, Melanie
Mayoux, Maud
Dumontet, Charles
Paiva, Bruno
Martinet, Ludovic
Leclair, Stephane
Xu, Wei
Klein, Christian
Umana, Pablo
BLOOD, 2022, 140 : 2091 - 2092
[38] Efficacy and preclinical safety of ARB202, a potential first-in-class anti-CDH17/CD3 bispecific T-cell engager, for treatment of pancreatic and colorectal cancers.
Wong, Dennis A.
Luk, Moon Ching
Wong, Tony K.
Staunton, Donald E.
Harlan, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[39] A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
D'Souza, Anita
Shah, Nina
Rodriguez, Cesar
Voorhees, Peter M.
Weisel, Katja
Bueno, Orlando F.
Pothacamury, Rajvineeth K.
Freise, Kevin J.
Yue, Susan
Ross, Jeremy A.
Polepally, Akshanth R.
Talati, Chetasi
Lee, Shane
Jin, Ziyi
Buelow, Ben
Vij, Ravi
Kumar, Shaji
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3576 - +
[40] Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Nakamura, Rin
Lear, Sean
Wilson, Deanna
Koeppen, Hartmut
Vaze, Anjali
Trudel, Suzanne
Spencer, Andrew
Harrison, Simon J.
Cohen, Adam D.
Fine, Bernard M.
Li, Mengsong
Cooper, James
Sumiyoshi, Teiko
BLOOD, 2020, 136

← 1 2 3 4 5 →